AstraZeneca-backed Alexion completed the acquisition of LogicBio Therapeutics for $68m.

AstraZeneca-backed Alexion, an American pharmaceutical company, completed the acquisition of LogicBio Therapeutics, a genomic medicine company, for $68m. The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in pre-clinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development.